A London-based FTSE 100 firm is adjusting policies due to being the top customer of the US government. GSK, led by Emma Walmsley, paused diversity activities in response to US executive orders. The move contrasts with British rival AstraZeneca's stance on diversity.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay